Study summary · research use only
Afamelanotide: A Review in Erythropoietic Protoporphyria
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
This review summarizes clinical trial data on afamelanotide (SCENESSE), a synthetic α-melanocyte stimulating hormone analogue and melanocortin-1 receptor agonist, administered as a subcutaneous biodegradable implant containing 16 mg, for prevention of phototoxicity in adults with erythropoietic protoporphyria (EPP) (human patients). In the phase III CUV039 trial, afamelanotide treatment was associated with improved light tolerance, more time spent in direct sunlight without pain, and increased time to first phototoxicity symptoms compared with placebo. Commonly reported adverse reactions included headache and implant-site reactions, and no drug-related serious adverse events were reported in this trial. The review states data from earlier phase III trials were consistent with the CUV039 trial findings.
Abstract
Afamelanotide (SCENESSE(®)) is a synthetic α-melanocyte stimulating hormone analogue and first-in-class melanocortin-1 receptor agonist that is approved in the EU for the prevention of phototoxicity in adults with erythropoietic protoporphyria (EPP). It is administered subcutaneously as a biodegradable, controlled-release implant containing 16 mg of afamelanotide. This article reviews the clinical efficacy and tolerability of afamelanotide in EPP and summarizes its pharmacological properties. In the phase III trial, CUV039, afamelanotide treatment improved light tolerance in patients with EPP. Compared with placebo, afamelanotide treatment enabled patients to spend more time in direct sunlight without pain and increased the time to the appearance of the first symptoms of phototoxicity provoked by a standardized light source. Afamelanotide was generally well tolerated in this trial, with no drug-related serious adverse events reported. Commonly occurring adverse reactions included headache and implant-site reactions. Efficacy and safety data from earlier phase III trials are consistent with those from the CUV039 trial. Afamelanotide, approved in the EU for the prevention of EPP phototoxicity, represents a useful addition to the management of the disorder.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.